UNODC
Conference on Fraudulent Medicines

William S. Reid
Senior Director, Global Anti-Counterfeiting Operations
Eli Lilly and Company

15 February 2013
Outline

1. Our engagement

2. Current challenges in fighting counterfeit medicines

3. Case studies

4. Conclusions
Our Engagement

• Anti-counterfeiting is an industry priority
  ✓ IFPMA Ten Principles
  ✓ Partnerships
  ✓ Policy research
  ✓ Awareness raising

• Support to WHO initiatives
Our Ten Principles

- Medicine counterfeiting is first and foremost a crime against patients
- Counterfeit medicines threaten the full spectrum of legitimate medicines
- Patents have nothing to do with counterfeiting and counterfeiting has nothing to do with patents
- Global cooperation is needed
- WHO leadership is critical
Our Recent Initiatives

UCL policy report: Falsified medicines and global public’s health

Position on Internet Sales and Access to Safe Medicines

FIP-IFPMA Document: The threat of false friends

Workshop: The threat of false friends Fake medicine - Imminent Risks to Global Health
Current Challenges

a. Detection of counterfeit medicines requires control of supply chain and enhanced regulatory capacity

b. Lack of global data and health impact assessment require regular reporting from competent authorities and other organizations

c. Robust and adapted legislative and regulatory frameworks require continuous enforcement efforts at national and international level
Case Studies

a. Scope: global, multiple therapeutic areas, patented and generic medicines
b. Illegitimate Internet sales
c. Unregulated API
d. Legislative challenges: Jurisdictional alignment, statutory limitations, domestic resource constraints
e. Opportunities: New technology & tools, growing awareness and actions, shared commitment to patient safety
Conclusions

- Robust Regulatory Framework and Enforcement
- Education and Awareness Raising
- Capacity Building
- International multi-sector Cooperation
Thank you